Status:
COMPLETED
The Effect of Primary Care Opioid Taper Plans on Sustained Opioid Taper
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
University of Washington
Conditions:
Opiate Replacement Therapy
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to examine the effects of opioid taper plans as documented in the electronic medical record for Kaiser Permanente Washington (KPWA) patients. The study will compare diff...
Detailed Description
Opioid taper is now encouraged by many health care organizations, but it is unclear if explicit plans for opioid taper by primary care providers are effective at promoting tapering or discontinuation,...
Eligibility Criteria
Inclusion
- A cohort of patients enrolled in Kaiser Permanente Washington who were receiving high dose, long-term opioid therapy (LtOT) for treatment of chronic non-cancer pain during 2010-2017. High dose LtOT defined above.
- Patients must be age \>18 years as of cohort entry and enrolled for at least 18 months during the study period.
Exclusion
- Patients under 18 years old
- Patients with any cancer diagnosis, hospice, nursing home care, methadone maintenance, buprenorphine for opioid use disorder, cognitive impairment, spinal cord stimulator, or intrathecal opioids.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2019
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT03748862
Start Date
January 1 2018
End Date
March 31 2019
Last Update
August 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Washington Health Research Institute
Seattle, Washington, United States, 98101